{
  "id": 16585275,
  "title": "Innovent presents clinical data for bispecific fusion protein IBI363",
  "url": "https://urgent.news/2026/10/26/innovent-presents-clinical-data-for-bispecific-fusion-protein-ibi363",
  "topic": "business",
  "section": "Business",
  "published": "2026-10-26T09:02:04.000Z",
  "source": {
    "name": "Vietnam Investment Review",
    "slug": "vietnam-investment-review",
    "url": "https://vir.com.vn/innovent-presents-clinical-data-for-bispecific-fusion-protein-ibi363-163673.html"
  },
  "original_language": "en",
  "account": "San Francisco and Suzhou, China, October 26, 2026 - Innovent Biologics, Inc. (HKEX Stock Code: 01801) presented multiple clinical data updates for IBI363, a potential first-in-class PD-1/alpha-biased IL-2 bispecific fusion protein, at the 2026 European Society for Medical Oncology (ESMO) Congress. Developed jointly by Innovent and Takeda, IBI363/TAK-928 showed promising results in lung and gastric cancer studies. Dr. Hui Zhou, Chief R&D Officer of Innovent, highlighted the broad antitumor potential of IBI363/TAK-928. The company plans to continue advancing its global development and seek new treatment options for patients.",
  "summary": "Innovent Biologics released updated clinical trial metrics at ESMO 2026 for IBI363 TAK 928 a bispecific fusion protein engineered to treat advanced solid malignancies",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}